WO2011159100A3 - 항암 활성을 나타내는 약제학적 조성물 - Google Patents

항암 활성을 나타내는 약제학적 조성물 Download PDF

Info

Publication number
WO2011159100A3
WO2011159100A3 PCT/KR2011/004382 KR2011004382W WO2011159100A3 WO 2011159100 A3 WO2011159100 A3 WO 2011159100A3 KR 2011004382 W KR2011004382 W KR 2011004382W WO 2011159100 A3 WO2011159100 A3 WO 2011159100A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
present
phenformin
side effects
active ingredient
Prior art date
Application number
PCT/KR2011/004382
Other languages
English (en)
French (fr)
Other versions
WO2011159100A2 (ko
Inventor
김성욱
전성수
민창희
구자성
김진욱
김용은
선상욱
Original Assignee
한올바이오파마주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110057664A external-priority patent/KR101275258B1/ko
Application filed by 한올바이오파마주식회사 filed Critical 한올바이오파마주식회사
Priority to US14/004,746 priority Critical patent/US20140235559A1/en
Publication of WO2011159100A2 publication Critical patent/WO2011159100A2/ko
Publication of WO2011159100A3 publication Critical patent/WO2011159100A3/ko
Priority to US13/930,800 priority patent/US20140235558A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 펜포르민 또는 그의 약제학적으로 허용 가능한 염과, 2-데옥시-D-글루코스를 활성 성분으로 포함하고, 항암 활성을 나타내는 약제학적 조성물에 관한 것이다. 이러한 약제학적 조성물은 각 활성 성분들간의 상승 작용을 통해 각각의 단일 활성 성분만을 사용하였을 경우에 비하여 훨씬 우수한 항암 효과를 나타냄과 동시에, 투여량이 감소되어 약물에 따른 부작용을 감소시킬 수 있다. 또한, 본 발명은 활성성분의 시간차 방출 또는 시간차 투여를 통해 펜포르민에 의한 유산산증과 같은 부작용을 현저히 감소시킬 수 있다. 특히 본 발명에 따른 약제학적 조성물은 환자의 복약 순응도 또한 상승하여, 각종 암을 치료하는데 매우 유용하게 사용될 수 있다.
PCT/KR2011/004382 2010-06-15 2011-06-15 항암 활성을 나타내는 약제학적 조성물 WO2011159100A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/004,746 US20140235559A1 (en) 2010-06-15 2011-06-15 Anti-cancer pharmaceutical composition
US13/930,800 US20140235558A1 (en) 2010-06-15 2013-06-28 Pharmaceutical composition having activity of anticancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20100056726 2010-06-15
KR10-2010-0056726 2010-06-15
KR20100078338 2010-08-13
KR10-2010-0078338 2010-08-13
KR10-2011-0057664 2011-06-14
KR1020110057664A KR101275258B1 (ko) 2010-06-15 2011-06-14 항암 활성을 나타내는 약제학적 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/004,746 A-371-Of-International US20140235559A1 (en) 2010-06-15 2011-06-15 Anti-cancer pharmaceutical composition
US13/930,800 Continuation-In-Part US20140235558A1 (en) 2010-06-15 2013-06-28 Pharmaceutical composition having activity of anticancer

Publications (2)

Publication Number Publication Date
WO2011159100A2 WO2011159100A2 (ko) 2011-12-22
WO2011159100A3 true WO2011159100A3 (ko) 2012-05-03

Family

ID=45348747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004382 WO2011159100A2 (ko) 2010-06-15 2011-06-15 항암 활성을 나타내는 약제학적 조성물

Country Status (1)

Country Link
WO (1) WO2011159100A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US20120177730A1 (en) * 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
WO2014083095A1 (en) * 2012-11-29 2014-06-05 Universitaet Basel Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035928A1 (en) * 2000-05-03 2006-02-16 Amgen Inc. Combination therapeutic compositions and methods of use
EP1881000A1 (en) * 2006-07-17 2008-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents
KR20090038389A (ko) * 2006-02-17 2009-04-20 엑쎄스 리미티드 비구아니드를 포함하는 펩티드 경구 전달용 용해 보조제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035928A1 (en) * 2000-05-03 2006-02-16 Amgen Inc. Combination therapeutic compositions and methods of use
KR20090038389A (ko) * 2006-02-17 2009-04-20 엑쎄스 리미티드 비구아니드를 포함하는 펩티드 경구 전달용 용해 보조제
EP1881000A1 (en) * 2006-07-17 2008-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents

Also Published As

Publication number Publication date
WO2011159100A2 (ko) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2013019058A3 (en) Pharmaceutical composition for inhibiting cancer recurrence or metastasis
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2015515475A5 (ko)
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
JP2013516493A5 (ko)
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2010098627A3 (ko) 약제학적 제제
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
WO2012053768A3 (en) Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2012064159A3 (ko) 항암용 조성물
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
PH12014502836A1 (en) Medicament form for release of active ingredients
ES2325291A1 (es) "uso de un extracto de silybum marianum"
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2013005482A (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
WO2011014009A3 (ko) 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
WO2010142400A3 (de) Zusammensetzungen auf basis von chitosan-oligosacchariden
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11795966

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11795966

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14004746

Country of ref document: US